Spyre Therapeutics (SYRE) Other Gross PP&E Adjustments: 2015-2024
Historic Other Gross PP&E Adjustments for Spyre Therapeutics (SYRE) over the last 8 years, with Dec 2024 value amounting to -$7.1 million.
- Spyre Therapeutics' Other Gross PP&E Adjustments fell 67.55% to -$7.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$21.2 million, marking a year-over-year decrease of 57.65%. This contributed to the annual value of -$7.1 million for FY2024, which is 67.55% down from last year.
- As of Q4 2024, Spyre Therapeutics' Other Gross PP&E Adjustments stood at -$7.1 million, which was down 67.55% from -$4.2 million recorded in Q4 2023.
- In the past 5 years, Spyre Therapeutics' Other Gross PP&E Adjustments registered a high of $1.3 million during Q4 2020, and its lowest value of -$7.1 million during Q4 2024.
- Its 3-year average for Other Gross PP&E Adjustments is -$4.6 million, with a median of -$5.3 million in 2022.
- Its Other Gross PP&E Adjustments has fluctuated over the past 5 years, first surged by 151.84% in 2020, then crashed by 762.40% in 2023.
- Over the past 5 years, Spyre Therapeutics' Other Gross PP&E Adjustments (Quarterly) stood at $1.3 million in 2020, then crashed by 40.52% to $778,000 in 2021, then dropped by 17.61% to $641,000 in 2022, then plummeted by 762.40% to -$4.2 million in 2023, then crashed by 67.55% to -$7.1 million in 2024.
- Its last three reported values are -$7.1 million in Q4 2024, -$4.2 million for Q4 2023, and -$6.0 million during Q2 2023.